SPONSOR
Beijing InnoCare Pharma Tech Co., Ltd.
Total Trials
3
Recruiting
3
Phases
Phase 3, Phase 2, Phase 1, Phase 2
Conditions studied: Treatment-naїve Mantle Cell LymphomaRelapsed or Refractory Mantle Cell Lymphoma (MCL)Relapsed and/or Refractory Multiple Myeloma
NCT05051891 Phase 3
Recruiting
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Treatment-naїve Mantle Cell Lymphoma
NCT07082686 Phase 2
Recruiting
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
NCT05719701 Phase 1, Phase 2
Recruiting
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
Relapsed and/or Refractory Multiple Myeloma